TABLE 5.
Mode of administration | Immune functiona | Reference(s) |
---|---|---|
In vivo | ||
Humans | ↓Antimicrobial activity | 14 |
↑↓Cytokine production | 14 | |
Rodents | ↓Lymphoproliferation | 20, 21, 171 |
↓Antibody formation | 166, 253 | |
↓DTH | 253 | |
↓↑Humoral immunity | 11 | |
↑↓Cytokine production | 250 | |
In vitro | ||
Humans | ↑HIV replication | 12, 177 |
↓Lymphocyte proliferation | 23, 49, 109 | |
↓Cytokine production | 131, 132 | |
Rodents | ↓Cytokine production | 250, 254, 262 |
↓Lymphocyte proliferation | 262 | |
↓NK activity | 262 |
↑, increase; ↓, decrease; ↑↓, both increase and decrease; DTH, delayed-type hypersensitivity.